GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » Float Percentage Of Total Shares Outstanding

Merck (MRK) Float Percentage Of Total Shares Outstanding : 99.96% (As of Apr. 27, 2024)


View and export this data going back to 1949. Start your Free Trial

What is Merck Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Merck's float shares is 2,532.10 Mil. Merck's total shares outstanding is 2,533.03 Mil. Merck's float percentage of total shares outstanding is 99.96%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Merck's Insider Ownership is 0.15%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Merck's Institutional Ownership is 46.99%.


Merck Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Merck's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=2,532.10/2,533.03
=99.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck (MRK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » Float Percentage Of Total Shares Outstanding
Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Executives
Johannes Jacobus Oosthuizen officer: SVP, U.S. Market 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard R. Deluca officer: EVP&Pres, Merck Animal Heallth 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steven Mizell officer: EVP,Human Resources 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Joseph Romanelli officer: President, Human Health Int?l 126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Rita A Karachun officer: Sr. VP Fince-Global Controller 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jennifer Zachary officer: EVP, General Counsel 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams officer: EVP,Chief Info&Digital Officer MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Robert M Davis officer: Evp, Global Svcs & CFO 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sanat Chattopadhyay officer: Exe V-P & Pres. MMD 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kenneth C Frazier officer: Chairman, President & CEO 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Chirfi Guindo officer: Chief Marketing Officer C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr director 370 WBASHA ST NORTH, ST PAUL MN 55102
Arpa Garay officer: SVP Human Health Global Mktg. 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield officer: EVP & CFO 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Julie L. Gerberding officer: EVP Strat Comm, GI Pub Policy 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033

Merck (MRK) Headlines

From GuruFocus

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at ASCO Annual Meeting Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Investor Event at ASCO 2023 Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024